Kyverna Therapeutics, Inc. KYTX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -74.5%— | -64.7%— | —— | —— | —— | |
| Return on assets | -60.4%— | -53.9%— | -61.2%— | —— | —— | |
| Return on invested capital | -94.5%— | -116.4%— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 8.1×+0.7× | 7.8×-0.9× | 5.2×-5.3× | 5.4×— | 7.4×— | |
| Quick ratio | 8.1×+0.7× | 7.8×-0.9× | 5.2×-5.3× | 5.4×— | 7.4×— | |
| Cash ratio | 1.1×-0.6× | 3.4×+0.5× | 1×-2.4× | 1.3×— | 1.7×— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×— | 0×— | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×— | 0×— | |
| Interest coverage | -144.7×+1,161× | -346.6×+658× | -2,350.5×-1,592× | -1,751.3×— | -1,306.1×— | |
| Per Share | ||||||
| Book value per share | $3.24-37.6% | $5.25-24.5% | $3.50-50.1% | $4.27-44.8% | $5.18-65.9% | |
| Valuation | ||||||
| Market capitalization | $498.52M+276% | $560.3M+247% | $259.47M— | $137.87M— | $83.32M— | |
| Enterprise value | $475.49M+475% | $440.81M+497% | $230.33M— | $90.35M— | $33.39M— | |
| Price / book | 2.5×+2.0× | 2.4×+1.8× | 1.7×— | 0.7×— | 0.4×— | |
| Earnings yield | -31.4%+78.2pp | -28.8%+50.2pp | -62%— | -115.1%— | -174.5%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Kyverna Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Kyverna Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.